300294SZSE

Announcement on Company Obtaining Drug Clinical Trial Approval Notice

China Resources Boya Bio-pharmaceutical Group Co.,Ltd·February 24, 2026·2 pages

✨ AI Summary

The company has received a drug clinical trial approval notice from the National Medical Products Administration for human coagulation factor IX. This approval allows the company to commence clinical trials for the treatment of bleeding in patients with Factor IX deficiency (Hemophilia B). The company has invested approximately RMB 16.32 million in R&D for this project.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

CR BOYA-BIO Stock Code: 300294 Stock Abbreviation: Boya Bio Announcement No.: 2026-005 CR Pharma Boya Bio Pharmaceutical Group Co., Ltd. Announcement on Company Obtaining Drug Clinical Trial Approval Notice

The Company and all members of the Board of Directors guarantee the authenticity, accuracy, and completeness of the announcement, and that there are no false records, misleading statements, or material omissions.

Recently, CR Pharma Boya Bio Pharmaceutical Group Co., Ltd. (hereinafter referred to as the Company) received the "Drug Clinical Trial Approval Notice" (Notice No.: 2026LP00442) for human coagulation factor IX, issued by the National Medical Products Administration. The relevant situation is hereby announced as follows:

I. Basic Information of the Drug

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.